Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11748MR)

This product GTTS-WQ11748MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11748MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2569MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ10539MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ4896MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ11824MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ4399MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ2523MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ415MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ6882MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA E-6011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW